Calypte acts to comply with FDA warning letter:
This article was originally published in Clinica
Executive Summary
Calypte Biomedical is taking action to comply with an FDA warning letter listing significant deviations from Federal regulations in the operation of its newly-acquired plant in Rockville, Maryland. The warning letter was based on inspections of the Rockville plant made in November and December 1998, when it was owned and operated by Cambridge Biotech, a subsidiary of bioMerieux Vitek. Calypte says it has responded in writing to many of points raised by the FDA and is rectifying the remaining issues.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.